Key result
CRISPR cuts pathogenic proteins ~90%, while RNA interference shows the most clinical promise for cardiomyopathy.
Why the study?
Does gene therapy improve cardiac function or correct disease-causing mutations in patients and models with cardiomyopathies?
Does gene therapy improve cardiac function or correct disease-causing mutations in patients and models with cardiomyopathies?
Gene therapy platforms offer promising mutation-specific treatments for various cardiomyopathies, with ATTR-CM therapies already showing clinical efficacy and safety.
Encourages CRISPR gene editing development for ATTR-CM; leaves open need for Phase 3 outcome trials.
Cardiomyopathies can be treated with gene therapy by correcting disease-causing mutations or reducing harmful gene products. To evaluate therapeutic progress and feasibility, this study compares current evidence between hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and transthyretin amyloid cardiomyopathy (ATTR-CM). In my hypothesis, gene-editing platforms such as CRISPR, base editing, prime editing, RNA interference, gene replacement therapy, and epigenome editing can provide mutation-specific benefits that improve cardiac function regardless of the subtype of cardiomyopathy. Most cases of HCM are caused by mutations in sarcomeres, including MYH7 and MYBPC3. Recent base editing studies have demonstrated successful correction of MYH7 mutations in human cardiomyocytes and humanized mice, restoring structural and functional parameters. A further demonstration of the accuracy and feasibility of targeted correction is provided by the use of CRISPR/Cas9 editing of MYBPC3 (R820W) in feline induced pluripotent stem cells. Prime editing has demonstrated strong potential for treating RBM20-related DCM. Researchers used a single pegRNA to repair multiple RBM20 variants in two cell-based studies, suggesting a versatile therapeutic approach to correct the P633L mutation of RBM20. ATTR-CM is the most advanced clinical trial. Approximately 90% of pathogenic proteins were reduced in a Phase 1 trial based on CRISPR-based TTR editing, with favorable early safety results. RNA-silencing therapy (vutrisiran) similarly stabilized cardiac biomarkers in ongoing clinical analyses.
No takes yet. Share an insight, caveat, or question.
Krisha Patel (2026) conducted a review in Cardiomyopathy. Gene therapy (CRISPR-Cas9, base editing, prime editing, RNA interference, gene replacement, epigenome editing) vs. Conventional therapy was evaluated. CRISPR-based gene editing reduced pathogenic proteins by approximately 90% in a Phase 1 trial, while RNA interference emerged as the most clinically promising therapy for cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: